[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-336837-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-336837-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","a-molecular-switch-from-tumor-suppressor-to-oncogene-in-erve-breast-cancer-role-of-androgen-receptor-jak-stat-and-lineage-plasticity","A molecular switch from tumor suppressor to oncogene in ER+ve breast cancer - Role of androgen receptor, JAK-STAT, and lineage plasticity","","The study investigates how the androgen receptor (AR), a ligand-activated tumor suppressor in ER-positive breast cancer, can drive resistance rather than sustained inhibition. By activating AR in ER-positive breast cancer xenografts, researchers observe cistrome reprogramming, oncogenic pathway suppression, and changes toward a more differentiated state. Sustained AR activation, however, rearranges the AR cistrome toward PROP paired-like homeobox 1, transforms AR into an oncogene, activates JAK/STAT signaling, and promotes lineage plasticity into an aggressive resistant subtype.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/a-molecular-switch-from-tumor-suppressor-to-oncogene-in-erve-breast-cancer-role-of-androgen-receptor-jak-stat-and-lineage-plasticity/336837/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/a-molecular-switch-from-tumor-suppressor-to-oncogene-in-erve-breast-cancer-role-of-androgen-receptor-jak-stat-and-lineage-plasticity/336837.png","ImageObject",300,407,{"name":42,"@type":43},"Rowan","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-06","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why does sustained AR activation lead to aggressive resistance in ER-positive breast cancer?","Question",{"text":63,"@type":64},"Sustained AR activation causes cistrome rearrangement toward PROP paired-like homeobox 1, transformation of AR into an oncogene, and activation of the JAK/STAT pathway. These changes culminate in lineage plasticity to an aggressive resistant subtype.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does the molecular portrait differ between AR-agonist–sensitive and resistant tumors?",{"text":68,"@type":64},"The molecular profile associated with AR-agonist sensitivity corresponds to better patient survival, while the resistant phenotype profile corresponds to shorter survival.",{"name":70,"@type":61,"acceptedAnswer":71},"What therapeutic implication does the work suggest for AR agonists and resistant cancers?",{"text":72,"@type":64},"Inhibiting activated oncogenes in resistant tumors reduces growth and resensitizes them to AR agonists. The study also proposes combinatorial approaches to manage resistance while using AR-agonist-like drugs.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},336837,1790299483,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":113,"preview_page_count":33,"preview_urls":145},1099514067415,"https://ap-avatar.wpscdn.com/avatar/100002539d78ffe74a7?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779092875211072502","A molecular switch from tumor suppressor to oncogene in ER+ve breast cancer: Role of androgen receptor, JAK-STAT, and lineage plasticity  \nSarah Asemotaa, Wendy Effaha, Jeremiah Holta, Daniel Johnsonb, Linnea Cripec , Suriyan Ponnusamya , Thirumagal Thiyagarajana, Yekta Khosrosereshkia, Dong-Jin Hwangd , Yali Hed, Brandy Grimese, Martin D. Flemingc, Frances E. Pritchardc, Ashley Hendrixc, Meiyun Fanf, Abhinav Jaing , Hyo Young Choih, i,  \nLiza Makowskia, h, D. Neil Hayesa, h, Duane D. Millerd, h, Lawrence M. Pfefferf, h, Balaji Santhanamj , and Ramesh Narayanana, h,1 Affiliations are included on p. 11.  \nEdited by Kornelia Polyak, Dana-Farber Cancer Institute, Boston, MA; received April 10, 2024; accepted August 19, 2024  \nCancers develop resistance to inhibitors of oncogenes mainly due to target-centric mechanisms such as mutations and splicing. While inhibitors or antagonists force targets to unnatural conformation contributing to protein instability and resistance, activating tumor suppressors may maintain the protein in an agonistic conformation to elicit sustainable growth inhibition. Due to the lack of tumor suppressor agonists, this hypothesis and the mechanisms underlying resistance are not understood. In estrogen receptor (ER)-positive breast cancer (BC), androgen receptor (AR) is a druggable tumor suppressor offering a promising avenue for this investigation. Spatial genomics suggests that the molecular portrait ofAR-expressing BC cells in tumor microenvironment corresponds to better overall patient survival, clinically confirming AR’s role as a tumor suppressor. Ligand activation of AR in ER-positive BC xenografts reprograms cistromes, inhibits oncogenic pathways, and promotes cellular elasticity toward a more differentiated state. Sustained AR activation results in cistrome rearrangement toward transcription factor PROP paired-like homeobox 1, transformation ofAR into oncogene, and activation of the Janus kinase/signal transducer (JAK/STAT) pathway, all culminating in lineage plasticity to an aggressive resistant subtype. While the molecular profile of AR agonist– sensitive tumors corresponds to better patient survival, the profile represented in the resistant phenotype corresponds to shorter survival. Inhibition of activated oncogenesin resistant tumors reduces growth and resensitizes them to AR agonists. These findings indicate that persistent activation of a context-dependent tumor suppressor may lead to resistance through lineage plasticity-driven tumor metamorphosis. Our work provides a framework to explore the above phenomenon across multiple cancer types and underscores the importance of factoring sensitization of tumor suppressor targets while developing agonist-like drugs.  \nandrogen receptor | estrogen receptor | breast cancer | JAK STAT | tumor suppressor  \nTargeted therapies for cancer rely on antagonists or inhibitors of oncogenes. Proteins in nature exist in an apo/holo or an activated conformation. Hence, the antagonist conformation of proteins is unnatural and likely unstable. This instability results in the oncogene reverting to its agonistic conformation by either mutating its binding residues, alternatively splicing to produce aggressively tumor-promoting variants, or utilizing a closely related protein to overcome the inhibition (1–3). Alternate strategies to treat cancer with an agonist of tumor suppressor will be ideal to maintain the protein in its natural agonistic conformation. Tumor suppressors currently are not pharmacological targets, making cancer treatment reliant on the strategy of deactivating oncogenes. Breast cancer (BC) is a classic example that has relied on antagonists or inhibitors of various proteins, including estrogen receptor (ER), aromatase (4–6), mammalian target of rapamycin (mTOR) (7, 8), human epidermal growth factor receptor 2 (EGFR/HER2) tyrosine kinases (9, 10), cyclin dependent kinase (CDK4/6) (11, 12), and Poly (ADP ribose) polymerase (PARP) (4, 13–15) . The excep","cbCaiuJJXIC4Hyre","https://ap.wps.com/l/cbCaiuJJXIC4Hyre","pdf",3809749,12,"English","# Significance\n## Molecular portrait and resistance outcome\n## Mechanistic links: AR, PROP-1, and JAK/STAT\n## Translational implications for combinatorial treatment","[{\"question\":\"Why does sustained AR activation lead to aggressive resistance in ER-positive breast cancer?\",\"answer\":\"Sustained AR activation causes cistrome rearrangement toward PROP paired-like homeobox 1, transformation of AR into an oncogene, and activation of the JAK/STAT pathway. These changes culminate in lineage plasticity to an aggressive resistant subtype.\"},{\"question\":\"How does the molecular portrait differ between AR-agonist–sensitive and resistant tumors?\",\"answer\":\"The molecular profile associated with AR-agonist sensitivity corresponds to better patient survival, while the resistant phenotype profile corresponds to shorter survival.\"},{\"question\":\"What therapeutic implication does the work suggest for AR agonists and resistant cancers?\",\"answer\":\"Inhibiting activated oncogenes in resistant tumors reduces growth and resensitizes them to AR agonists. The study also proposes combinatorial approaches to manage resistance while using AR-agonist-like drugs.\"}]","A molecular switch from tumor suppressor to oncogene in ER+ve breast cancer - Role of androgen receptor, JAK-STAT, and lineage plasticity | PDF",1790016811,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d50219573fd570940f6f418b2c1bb2a3.webp",983,1316,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4c0c0cea3dd7d4b74b3161dfd138818e.webp",982,1315,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/167366c97337c82af4cb9d7a97b54464.webp",981,1313,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e8ea8daf1ae7b370bb80ac30b1b03859.webp",980,1312]